Evidence map›Paper›PMID 31434680›Full record

ReviewGenome research2019

Decrypting noncoding RNA interactions, structures, and functional networks.

Muller Fabbri, Leonard Girnita, Gabriele Varani, George A Calin

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Genome research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04767750 (Role of LncRNA H19 in The Regulation of IGF-1R Expression), which is not on this map. Cited by 90 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04767750 completednot on this mapstarted 2020, after this paper: background citation

Role of LncRNA H19 in The Regulation of IGF-1R Expression: A Possible Association Between Type 2 Diabetes and Hepatocellular Carcinoma

TypeobservationalSponsorMansoura UniversityRan2020 to 2022Enrolled101ConditionsHepatocellular Carcinoma, Type 2 Diabetes, CancerArmsBlood sample collection
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Are RNA Therapies a Solid Foundation or a Frontier Yet to Be Conquered?International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Bioinformatics Approaches in Noncoding RNAs Research.Experientia supplementum (2012) · 2026
    Review
  11. Article
  12. Article
  13. Noncoding RNAs in periodontitis: Progress and perspectives (Review).International journal of molecular medicine · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Muller Fabbri *University of Hawaii Cancer Center, Cancer Biology Program, Honolulu, Hawaii 96813, USA.
Leonard Girnita *Department of Oncology-Pathology, Cellular and Molecular Tumor Pathology, Karolinska Institute, and Karolinska University Hospital, Stockholm, 17164 Sweden.
Gabriele VaraniDepartment of Chemistry, University of Washington, Seattle, Washington 98195-1700, USA.
George A CalinDepartment of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Karolinska University Hospital · SEThe University of Texas MD Anderson Cancer Center · USUniversity of Hawaiʻi at Mānoa · USUniversity of Washington · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
ncRNA: Structure, Interactions and InhibitionR35GM126942 · NIGMS · UNIVERSITY OF WASHINGTON · PI Gabriele Varani · 2018 to 2026
$6.0M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of NeuroblastomaR01CA215753 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI FABBRI, MULLER · 2017 to 2021
$1.7M
Clinical Significance and Mechanism of Action of Exosomal microRNAs in Neuroblastoma chemoresistanceR01CA219024 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI FABBRI, MULLER · 2018 to 2022
$1.7M
Regulation of microRNA processingR01GM103834 · NIGMS · UNIVERSITY OF WASHINGTON · PI VARANI, GABRIELE · 2014 to 2017
$1.1M
Viral miRs and cellular miRs in sepsisR01GM122775 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LUPU, FLOREA · 2018 to 2020
$1.1M
NCATS NIH HHS UH3 TR000943NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA182905NCI NIH HHS R01 CA215753NCI NIH HHS R01 CA219024NCI NIH HHS R01 CA222007NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIGMS NIH HHS R01 GM103834NIGMS NIH HHS R01 GM122775NIGMS NIH HHS R35 GM126942
6 · The paper itself

Abstract

The world of noncoding RNAs (ncRNAs) is composed of an enormous and growing number of transcripts, ranging in length from tens of bases to tens of kilobases, involved in all biological processes and altered in expression and/or function in many types of human disorders. The premise of this review is the concept that ncRNAs, like many large proteins, have a multidomain architecture that organizes them spatially and functionally. As ncRNAs are beginning to be imprecisely classified into functional families, we review here how their structural properties might inform their functions with focus on structural architecture-function relationships. We will describe the properties of "interactor elements" (IEs) involved in direct physical interaction with nucleic acids, proteins, or lipids and of "structural elements" (SEs) directing their wiring within the "ncRNA interactor networks" through the emergence of secondary and/or tertiary structures. We suggest that spectrums of "letters" (ncRNA elements) are assembled into "words" (ncRNA domains) that are further organized into "phrases" (complete ncRNA structures) with functional meaning (signaling output) through complex "sentences" (the ncRNA interactor networks). This semiotic analogy can guide the exploitation of ncRNAs as new therapeutic targets through the development of IE-blockers and/or SE-lockers that will change the interactor partners' spectrum of proteins, RNAs, DNAs, or lipids and consequently influence disease phenotypes.

Indexed as

DNAHumansModels, MolecularNucleic Acid ConformationProteinsRNA, UntranslatedDNAProteinsRNA, Untranslated

Identifiers

PMID31434680
PMCPMC6724670
OpenAlexW2972256305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.